



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



GSK1482160

Item No. 41980

CAS Registry No.: 1001389-72-5
Formal Name: (2S)-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-5-oxo-2-pyrrolidinecarboxamide
MF: C₁₄H₁₄ClF₃N₂O₂
FW: 334.7
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK1482160 is supplied as a solid. A stock solution may be made by dissolving the GSK1482160 in the solvent of choice, which should be purged with an inert gas. GSK1482160 is sparingly soluble (1-10 mg/ml) in DMSO and ethanol.

Description

GSK1482160 is an antagonist of the purinergic P2X₇ receptor (IC₅₀ = 3.2 nM for the human receptor).¹ It inhibits increases in the levels of reactive oxygen species (ROS) induced by LPS and BzATP (Item No. 15577) in THP-1 macrophages when used at a concentration of 1 μM.² GSK1482160 (20 mg/kg twice per day) decreases the accumulation of misfolded tau aggregates in the brain and improves learning and memory in the Y-maze and contextual fear conditioning tests in human P301S tau transgenic mice.³ It reverses mechanical allodynia in a rat model of chronic constriction injury-induced allodynia when administered at a dose of 20 mg/kg.¹

References

1. Abdi, M.H., Beswick, P.J., Billinton, A., *et al.* Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X₇ receptor. *Bioorg. Med. Chem. Lett.* **20(17)**, 5080-5084 (2010).
2. Homerin, G., Jawhara, S., Dezitter, X., *et al.* Pyroglutamide-based P2X7 receptor antagonists targeting inflammatory bowel disease. *J. Med. Chem.* **63(5)**, 2074-2094 (2020).
3. Ruan, Z., Delpech, J.-C., Venkatesan Kalavai, S., *et al.* P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice. *Mol. Neurodegener.* **15(1)**, 47 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/16/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM